FR23C1036I1 - Anticorps qui se lient à il-23 - Google Patents

Anticorps qui se lient à il-23

Info

Publication number
FR23C1036I1
FR23C1036I1 FR23C1036C FR23C1036C FR23C1036I1 FR 23C1036 I1 FR23C1036 I1 FR 23C1036I1 FR 23C1036 C FR23C1036 C FR 23C1036C FR 23C1036 C FR23C1036 C FR 23C1036C FR 23C1036 I1 FR23C1036 I1 FR 23C1036I1
Authority
FR
France
Prior art keywords
antibodies
bind
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR23C1036C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of FR23C1036I1 publication Critical patent/FR23C1036I1/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FR23C1036C 2013-03-08 2023-10-13 Anticorps qui se lient à il-23 Active FR23C1036I1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361774732P 2013-03-08 2013-03-08
PCT/US2014/020064 WO2014137962A1 (en) 2013-03-08 2014-03-04 Antibodies that bind il-23

Publications (1)

Publication Number Publication Date
FR23C1036I1 true FR23C1036I1 (fr) 2023-12-08

Family

ID=51488096

Family Applications (1)

Application Number Title Priority Date Filing Date
FR23C1036C Active FR23C1036I1 (fr) 2013-03-08 2023-10-13 Anticorps qui se lient à il-23

Country Status (40)

Country Link
US (3) US9023358B2 (zh)
EP (3) EP2964258B1 (zh)
JP (1) JP6096938B2 (zh)
KR (2) KR101775115B1 (zh)
CN (1) CN105307681B (zh)
AP (1) AP2015008708A0 (zh)
AR (1) AR094877A1 (zh)
AU (1) AU2014226094B2 (zh)
BR (1) BR112015019611B1 (zh)
CA (1) CA2901462C (zh)
CL (1) CL2015002388A1 (zh)
CY (2) CY1123589T1 (zh)
DK (1) DK2964258T3 (zh)
EA (1) EA031524B1 (zh)
EC (1) ECSP15038626A (zh)
ES (1) ES2822662T3 (zh)
FI (1) FIC20230030I1 (zh)
FR (1) FR23C1036I1 (zh)
HK (1) HK1212252A1 (zh)
HR (1) HRP20201633T1 (zh)
HU (2) HUE051357T2 (zh)
IL (2) IL240731B (zh)
JO (1) JOP20140049B1 (zh)
LT (1) LT2964258T (zh)
MA (1) MA38382A1 (zh)
MX (1) MX370396B (zh)
MY (1) MY171226A (zh)
NL (1) NL301247I2 (zh)
PE (1) PE20151529A1 (zh)
PH (1) PH12015501994A1 (zh)
PL (1) PL2964258T3 (zh)
PT (1) PT2964258T (zh)
RS (1) RS60928B1 (zh)
SG (1) SG11201507176VA (zh)
SI (1) SI2964258T1 (zh)
TN (1) TN2015000348A1 (zh)
TW (1) TWI636063B (zh)
UA (1) UA123198C2 (zh)
WO (1) WO2014137962A1 (zh)
ZA (1) ZA201505285B (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR102417A1 (es) * 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
EP3368066A1 (en) * 2015-10-30 2018-09-05 Eli Lilly and Company Anti-cgrp/anti-il-23 bispecific antibodies and uses thereof
AR111845A1 (es) 2017-05-03 2019-08-28 Lilly Co Eli Anticuerpos biespecíficos anti-cgrp / anti-il-23 y usos de los mismos
TWI744617B (zh) 2018-03-30 2021-11-01 美商美國禮來大藥廠 治療潰瘍性結腸炎之方法
TWI725532B (zh) 2018-09-11 2021-04-21 美商美國禮來大藥廠 治療牛皮癬之方法
TW202103734A (zh) 2019-04-22 2021-02-01 美商美國禮來大藥廠 治療克隆氏症（ｃｒｏｈｎ＇ｓ ｄｉｓｅａｓｅ）的方法
WO2021076620A1 (en) 2019-10-15 2021-04-22 Eli Lilly And Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
JP2023509373A (ja) 2019-12-20 2023-03-08 ノヴァロック バイオセラピューティクス， リミテッド 抗インターロイキン－２３ ｐ１９抗体およびそれの使用方法
CN111718414B (zh) * 2020-06-12 2021-03-02 江苏荃信生物医药有限公司 抗人白介素23单克隆抗体及其应用
WO2022041390A1 (zh) * 2020-08-28 2022-03-03 江苏荃信生物医药股份有限公司 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂及其制备方法
TW202224702A (zh) 2020-09-10 2022-07-01 美商美國禮來大藥廠 治療性抗體調配物
EP4347018A1 (en) 2021-05-28 2024-04-10 Eli Lilly and Company Anti-il-23p19 antibody regulation of genes involved in ulcerative colitis
CN113698480B (zh) * 2021-09-18 2022-07-01 东大生物技术(苏州)有限公司 一组il-23单克隆抗体及其医药用途
WO2023056417A1 (en) 2021-09-30 2023-04-06 Eli Lilly And Company Anti-il-23p19 antibody regulation of genes involved in bowel urgency in ulcerative colitis
WO2024077113A1 (en) 2022-10-06 2024-04-11 Eli Lilly And Company Methods of treating fatigue in ulcerative colitis

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
US7422743B2 (en) 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
CN1759123B (zh) 2003-03-10 2011-04-13 先灵公司 Il-23激动剂及拮抗剂的用途；相关试剂
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
EP1896073B1 (en) * 2005-06-30 2013-03-06 Janssen Biotech, Inc. Anti-il-23 antibodies, compositions, methods and uses
CN101248088A (zh) * 2005-08-25 2008-08-20 伊莱利利公司 抗il-23抗体
MX2008002179A (es) * 2005-08-25 2008-04-22 Lilly Co Eli Anticuerpos anti-il-23.
ES2619845T3 (es) 2005-08-31 2017-06-27 Merck Sharp & Dohme Corp. Anticuerpos anti-IL-23 diseñados por ingeniería genética
ES2517420T3 (es) * 2005-12-29 2014-11-03 Janssen Biotech, Inc. Anticuerpos anti-IL-23 humanos, composiciones, procedimientos y usos
CN103396489A (zh) * 2007-02-23 2013-11-20 默沙东公司 工程改造的抗IL-23p19抗体
HUE042172T2 (hu) * 2007-02-23 2019-06-28 Merck Sharp & Dohme Genetikailag elõállított anti-il-23P19 antitestek
BRPI0809026A2 (pt) * 2007-03-20 2014-09-23 Lilly Co Eli Anticorpos antiesclerotina
JP5290276B2 (ja) 2007-05-08 2013-09-18 ジェネンテック， インコーポレイテッド システイン改変抗ｍｕｃ１６抗体および抗体−薬物結合体
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
US20120264917A1 (en) * 2009-05-27 2012-10-18 Ablynx N.V. Biparatopic protein constructs directed against il-23
CN103282382B (zh) * 2010-11-04 2017-11-03 勃林格殷格翰国际有限公司 抗il‑23抗体
JP5987053B2 (ja) * 2011-05-12 2016-09-06 ジェネンテック， インコーポレイテッド フレームワークシグネチャーペプチドを用いて動物サンプルにおける治療抗体を検出するための多重反応モニタリングｌｃ−ｍｓ／ｍｓ法

Also Published As

Publication number Publication date
SG11201507176VA (en) 2015-10-29
PT2964258T (pt) 2020-11-06
NL301247I2 (nl) 2023-11-01
NL301247I1 (nl) 2023-10-11
CL2015002388A1 (es) 2016-03-04
CA2901462A1 (en) 2014-09-12
CN105307681A (zh) 2016-02-03
HRP20201633T1 (hr) 2020-12-25
KR20150113202A (ko) 2015-10-07
UA123198C2 (uk) 2021-03-03
JP6096938B2 (ja) 2017-03-15
EP4311558A2 (en) 2024-01-31
PL2964258T3 (pl) 2021-02-08
KR101775115B1 (ko) 2017-09-05
ES2822662T3 (es) 2021-05-04
MY171226A (en) 2019-10-03
ZA201505285B (en) 2017-11-29
MX370396B (es) 2019-12-11
EP2964258A1 (en) 2016-01-13
EP3789037A1 (en) 2021-03-10
PH12015501994A1 (en) 2016-01-11
CY1123589T1 (el) 2022-03-24
HUE051357T2 (hu) 2021-03-01
AU2014226094A1 (en) 2015-08-27
TW201520225A (zh) 2015-06-01
CY2023021I1 (el) 2024-02-16
FIC20230030I1 (fi) 2023-10-03
MA38382A1 (fr) 2017-11-30
IL272042A (en) 2020-02-27
AU2014226094B2 (en) 2016-06-23
JOP20140049B1 (ar) 2021-08-17
IL240731B (en) 2020-01-30
CA2901462C (en) 2017-07-25
US20170275356A1 (en) 2017-09-28
KR20170103037A (ko) 2017-09-12
US20150232552A1 (en) 2015-08-20
EA031524B1 (ru) 2019-01-31
RS60928B1 (sr) 2020-11-30
IL272042B (en) 2021-07-29
US20140255422A1 (en) 2014-09-11
US9023358B2 (en) 2015-05-05
WO2014137962A1 (en) 2014-09-12
BR112015019611A2 (pt) 2017-08-22
TWI636063B (zh) 2018-09-21
TN2015000348A1 (en) 2017-01-03
AP2015008708A0 (en) 2015-09-30
US9688753B2 (en) 2017-06-27
HUS2300036I1 (hu) 2023-11-28
JP2016510744A (ja) 2016-04-11
EA201591368A1 (ru) 2015-12-30
EP2964258B1 (en) 2020-09-02
MX2015011959A (es) 2016-04-07
DK2964258T3 (da) 2020-09-14
EP4311558A3 (en) 2024-04-10
HK1212252A1 (zh) 2016-06-10
LT2964258T (lt) 2020-10-12
BR112015019611B1 (pt) 2023-05-02
EP2964258A4 (en) 2016-10-12
AR094877A1 (es) 2015-09-02
NZ711147A (en) 2021-03-26
PE20151529A1 (es) 2015-10-28
SI2964258T1 (sl) 2020-10-30
ECSP15038626A (es) 2015-11-30
IL240731A0 (en) 2015-10-29
CN105307681B (zh) 2018-06-26

Similar Documents

Publication Publication Date Title
FR23C1036I1 (fr) Anticorps qui se lient à il-23
NO2021007I1 (no) calcifediol
DK3049441T3 (da) Anti-PDL1-antistofformuleringer
KR102355950B9 (ko) Tigit에 대한 항체
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
DK3336106T3 (da) Anti-fcrh5-antistoffer
MA47472A (fr) Anticorps
DK3708583T3 (da) Ikke-fucosylerede anti-fgfr2iiib-antistoffer
DK2970460T3 (da) Anti-IL-33-antistoffer og anvendelser deraf
DK3071595T3 (da) Humaniseret anti-kallikrein-2-antistof
FR3014362B1 (fr) Ensemble roulant perfectionne
DK3053119T3 (da) Papirløs anvendelse
DK3003386T3 (da) Antistoflægemiddelkonjugater
MA42843A (fr) Anticorps anti-cd115
CL2016001147A1 (es) Anticuerpos específicos para fcrn.
DK3047188T3 (da) Rørforbindelse
DK3065774T3 (da) Anti-CCL17-antistoffer
FR3002228B1 (fr) Anticorps monoclonal et utilisations
FI20130201A (fi) Veren kolesterolia alentava koostumus
FI20135464A (fi) Putkiliitos
TH1401006962A (th) แอนติ-ทรานสกลูตามิเนส 2 แอนติบอดี
FR3004184B1 (fr) Anticorps anti-gluten desamide et utilisations.
TH1401007591A (th) อิมมูโนคอนจูเกตที่ประกอบด้วยแอนติบอดีต้าน cd79b
TH1401007915B (th) วัสดุเสียดทาน (friction materail)
TH1401005842A (th) แอนติบอดีต่อ siglec-15 ที่ดัดแปลง cdr